• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.

作者信息

Koeckerling David, Pan Daniel, Barker Joseph

机构信息

Medical Sciences Division, University of Oxford, Oxfordshire, UK.

Department of Respiratory Sciences, University of Leicester, Leicester, UK; Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS Trust, UK.

出版信息

Clin Microbiol Infect. 2021 Aug;27(8):1175-1176. doi: 10.1016/j.cmi.2021.01.025. Epub 2021 Feb 5.

DOI:10.1016/j.cmi.2021.01.025
PMID:33549765
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7862016/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/7862016/fbee812451c9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/7862016/fbee812451c9/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4f7f/7862016/fbee812451c9/gr1_lrg.jpg

相似文献

1
Re: 'Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis' by Tleyjeh et al.
Clin Microbiol Infect. 2021 Aug;27(8):1175-1176. doi: 10.1016/j.cmi.2021.01.025. Epub 2021 Feb 5.
2
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.托珠单抗治疗新冠肺炎患者的疗效和安全性：一项实时系统评价与荟萃分析——作者回复
Clin Microbiol Infect. 2021 Aug;27(8):1177-1178. doi: 10.1016/j.cmi.2021.02.024. Epub 2021 Mar 8.
3
Efficacy and safety of tocilizumab in hospitalized COVID-19 patients: A systematic review and meta-analysis.托珠单抗治疗住院COVID-19患者的疗效和安全性：一项系统评价和荟萃分析。
J Infect. 2022 Mar;84(3):418-467. doi: 10.1016/j.jinf.2021.11.013. Epub 2021 Nov 20.
4
Reply to Tleyjeh.
Clin Infect Dis. 2021 Jun 15;72(12):e1155-e1156. doi: 10.1093/cid/ciaa1736.
5
In COVID-19, tocilizumab reduces all-cause mortality at 28 d.在 COVID-19 中，托珠单抗可降低 28 天全因死亡率。
Ann Intern Med. 2021 Jun;174(6):JC63. doi: 10.7326/ACPJ202106150-063. Epub 2021 Jun 1.
6
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析，首次更新。
Clin Microbiol Infect. 2021 Aug;27(8):1076-1082. doi: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
7
Safety concerns regarding concomitant use of tocilizumab and glucocorticoids in COVID-19 patients.关于在新冠病毒肺炎患者中同时使用托珠单抗和糖皮质激素的安全性问题。
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30025-30026. doi: 10.1073/pnas.2009253117. Epub 2020 Nov 12.
8
Association between tocilizumab treatment and clinical outcomes of COVID-19 patients: a systematic review and meta-analysis.托珠单抗治疗与 COVID-19 患者临床结局的相关性：系统评价和荟萃分析。
Aging (Albany NY). 2022 Jan 17;14(2):557-571. doi: 10.18632/aging.203834.
9
The effect of tocilizumab on COVID-19 patient mortality: A systematic review and meta-analysis of randomized controlled trials.托珠单抗对 COVID-19 患者死亡率的影响：一项随机对照试验的系统评价和荟萃分析。
Int Immunopharmacol. 2021 Jul;96:107602. doi: 10.1016/j.intimp.2021.107602. Epub 2021 Mar 24.
10
Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).评估托珠单抗（人源化单克隆抗体）治疗新型冠状病毒肺炎（COVID-19）患者的疗效和临床安全性。
Medicina (Kaunas). 2022 Aug 10;58(8):1076. doi: 10.3390/medicina58081076.

引用本文的文献

1
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis - Author's reply.托珠单抗治疗新冠肺炎患者的疗效和安全性：一项实时系统评价与荟萃分析——作者回复
Clin Microbiol Infect. 2021 Aug;27(8):1177-1178. doi: 10.1016/j.cmi.2021.02.024. Epub 2021 Mar 8.

本文引用的文献

1
Patterns of within-host genetic diversity in SARS-CoV-2.SARS-CoV-2 病毒在宿主内的遗传多样性模式。
Elife. 2021 Aug 13;10:e66857. doi: 10.7554/eLife.66857.
2
Tocilizumab in Hospitalized Patients with Severe Covid-19 Pneumonia.托珠单抗治疗重症 COVID-19 肺炎住院患者。
N Engl J Med. 2021 Apr 22;384(16):1503-1516. doi: 10.1056/NEJMoa2028700. Epub 2021 Feb 25.
3
Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic Immunocompromised Individual with Cancer.病例研究：一名患有癌症的无症状免疫功能低下个体长期感染性严重急性呼吸综合征冠状病毒2（SARS-CoV-2）脱落。
Cell. 2020 Dec 23;183(7):1901-1912.e9. doi: 10.1016/j.cell.2020.10.049. Epub 2020 Nov 4.
4
Persistence and Evolution of SARS-CoV-2 in an Immunocompromised Host.严重急性呼吸综合征冠状病毒2型在免疫功能低下宿主中的持续存在与演变
N Engl J Med. 2020 Dec 3;383(23):2291-2293. doi: 10.1056/NEJMc2031364. Epub 2020 Nov 11.
5
Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis.托珠单抗治疗 COVID-19 患者的疗效和安全性：一项实时系统评价和荟萃分析。
Clin Microbiol Infect. 2021 Feb;27(2):215-227. doi: 10.1016/j.cmi.2020.10.036. Epub 2020 Nov 5.
6
Within-Host Diversity of SARS-CoV-2 in COVID-19 Patients With Variable Disease Severities.COVID-19 患者中不同疾病严重程度与 SARS-CoV-2 的宿主内多样性。
Front Cell Infect Microbiol. 2020 Oct 6;10:575613. doi: 10.3389/fcimb.2020.575613. eCollection 2020.
7
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.托珠单抗对比常规治疗用于 COVID-19 成人患者伴中重度肺炎的随机临床试验
JAMA Intern Med. 2021 Jan 1;181(1):32-40. doi: 10.1001/jamainternmed.2020.6820.
8
Impact of interleukin-6 blockade with tocilizumab on SARS-CoV-2 viral kinetics and antibody responses in patients with COVID-19: A prospective cohort study.托珠单抗阻断白细胞介素 6 对 COVID-19 患者 SARS-CoV-2 病毒动力学和抗体反应的影响：一项前瞻性队列研究。
EBioMedicine. 2020 Oct;60:102999. doi: 10.1016/j.ebiom.2020.102999. Epub 2020 Sep 16.
9
After 62 years of regulating immunity, dexamethasone meets COVID-19.地塞米松调控免疫 62 年后迎击 COVID-19。
Nat Rev Immunol. 2020 Oct;20(10):587-588. doi: 10.1038/s41577-020-00421-x.